Amide Compounds for CNS Disorders with Extended Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CNS therapeutic agents for conditions like epilepsy, spasticity, and neuropathic pain often exhibit undesirable properties such as toxicity, short half-life, and severe side effects, limiting their efficacy and patient compliance.
Innovation Solution
Development of novel amides with a phenyl group attached via a short aliphatic linker, offering improved metabolic stability, longer half-life, and reduced toxicity, while maintaining or increasing biological activity, thus providing a superior side effect profile.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If currently available CNS therapeutic agents are used, then good CNS activity is achieved, but chronic toxicity and severe side effects occur
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of amide compounds - specifically changing the R groups attached to the carbonyl carbon and the aromatic substituents. These structural parameter changes result in compounds that maintain CNS activity while reducing toxicity and side effects, as demonstrated by the improved safety profile of the novel amides compared to existing therapeutics.
Solution Approach 2:
The invention creates composite molecular structures by combining a carbonyl group with various amino groups (R1R2N-) and aromatic systems. These composite amide structures provide the dual benefit of maintaining therapeutic CNS activity while incorporating structural features that reduce adverse effects and improve metabolic stability.
2Reliability
If currently available CNS therapeutic agents are used, then therapeutic effect is achieved, but pharmacokinetic properties are inadequate with short half-life
Solution Approach 1:
The patent extends half-life by changing molecular parameters - specifically by selecting R groups and aromatic substituents that increase lipophilicity and molecular weight within optimal ranges. These parameter changes enhance the compound's resistance to metabolic degradation and improve pharmacokinetic retention, resulting in longer half-life while maintaining therapeutic efficacy.
3Reliability
If dosing frequency is increased to sustain therapeutic concentrations, then therapeutic effect is maintained, but patient compliance decreases and therapy cost increases
Solution Approach 1:
The patent achieves continuous therapeutic action by designing amide compounds with extended half-life that maintain therapeutic concentrations for prolonged periods. This continuous action allows for reduced dosing frequency (e.g., once daily or less), improving patient compliance while maintaining reliable therapeutic effect without requiring frequent administration.
Solution Approach 2:
By optimizing molecular parameters such as lipophilicity, molecular weight, and metabolic stability of the amide compounds, the invention extends the duration of therapeutic action. This enables sustained therapeutic concentrations to be maintained with less frequent dosing, thereby improving ease of operation and patient compliance.
Data Source
Figure 1
Figure 2
Figure 3A
AI summary
A series of novel compounds showing anticonvulsant activity is described. Such pharmaceutically active compounds may also show utility in the treatment of other central nervous system ("CNS") diseases and disorders, such as anxiety, depression, insomnia, migraine headaches, schizophrenia, Parkinson's disease, spasticity, Alzheimer's disease, and bipolar disorder. Furthermore, such compounds may additionally find utility as analgesics (e.g., for the treatment of chronic or neuropathic pain) and as neuroprotective agents useful in the treatment of stroke(s), chronic neurodegenerative diseases (such as Alzheimer's disease and Huntington's disease), and/or traumatic brain and/or spinal cord injuries. Moreover, these/such compounds may also be useful in the treatment of status epilepticus and/or as chemical countermeasures.